ScreenerHero
ROMJRubicon Organics Inc.
TSXV · CA · Healthcare · Drug Manufacturers - Specialty & Generic · rubiconorganics.com
0.4400CAD-4.35%Mkt Cap: 23.13M $P/E: —

Rubicon Organics Inc., together with its subsidiaries, engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally. The company offers ca…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap23.13M $
Enterprise Value33.86M $
Revenue (TTM)46.78M $
Gross Profit16.12M $
Net Income (TTM)765.40K $
Revenue/Share0.6649 USD
Last Price0.4400 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees263
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)4.95
PEG—
EV/EBITDA18.32
EV/Revenue0.72
P/S0.57
P/B0.88
EPS (TTM)-0.02
EPS (Forward)0.11
52W Range
0.370019% of range0.7300
52W High0.7300 CAD
52W Low0.3700 CAD
Profitability
Gross Margin37.24%
Oper. Margin3.66%
EBITDA Margin3.95%
Profit Margin1.77%
ROE2.39%
ROA1.57%
Growth
Revenue Growth23.10%
Earnings Growth-41.80%
Cash Flow & Leverage
Operating CF-2.21M $
CapEx (TTM)6.13M $
FCF Margin-12.04%
FCF Yield-24.35%
Net Debt7.28M $
Net Debt/EBITDA3.94
Balance Sheet
Debt/Equity0.28
Current Ratio2.21
Quick Ratio0.80
Book Value/Sh0.6160 CAD
Cash/Share0.0820 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.150 CAD
Upside (mean)+161.4%
Target Range1.000 CAD – 1.300 CAD
CAD1.000+161.4% to meanCAD1.300
# Analysts2
Ownership
Shares Out.67.58M
Float39.08M
Insiders42.39%
Institutions3.36%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short10.52K
Short (prev mo.)52.85K
Technical
SMA 500.4610 (-4.6%)
SMA 2000.4770 (-7.8%)
Beta0.38
S&P 52W Chg18.16%
Avg Vol (30d)48.78K
Avg Vol (10d)155.02K
Technical Indicators
RSI (14)44.8
MACD0.0059
MACD Signal0.0067
MACD Hist.-0.0008
BB Upper0.5178 CAD
BB Middle0.4645 CAD
BB Lower0.4112 CAD
BB Width22.95%
ATR (14)0.0284 CAD
Vol Ratio (20d)1.42x